These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28197493)

  • 1. Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients.
    Annapareddy SN; Elumalai R; Lakkakula BV; Ramanathan G; Periyasamy S
    J Nephropharmacol; 2016; 5(1):13-18. PubMed ID: 28197493
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of angiotensin converting enzyme (
    Ramanathan G; Ghosh S; Elumalai R; Periyasamy S; Lakkakula BV
    Indian J Med Res; 2016 Jun; 143(6):748-755. PubMed ID: 27748299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone synthase gene is not a major susceptibility gene for progression of chronic kidney disease in patients with autosomal dominant polycystic kidney disease.
    Ramanathan G; Elumalai R; Periyasamy S; Lakkakula BVKS
    Saudi J Kidney Dis Transpl; 2017; 28(3):552-557. PubMed ID: 28540892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.
    Ramanathan G; Periyasamy S; Lakkakula BV
    Nephrology (Carlton); 2014 Sep; 19(9):537-41. PubMed ID: 24824375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.
    Gnanasambandan R; Elumalai R; Soundararajan P; Lakkakula BVKS
    Clin Exp Nephrol; 2016 Aug; 20(4):561-568. PubMed ID: 26482465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin gene rs1464816 polymorphism contributes to chronic kidney disease progression in ADPKD.
    Ramanathan G; Elumalai R; Periyasamy S; Lakkakula BV
    J Biomed Sci; 2016 Jan; 23():1. PubMed ID: 26753721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of endothelin-1 gene polymorphisms on the progression of autosomal dominant polycystic kidney disease.
    Reiterová J; Merta M; Stekrová J; Cabartová Z; Cibulka R; Maixnerová D; Rysavá R; Ríhová Z; Tesar V; Motán J
    Kidney Blood Press Res; 2006; 29(3):182-8. PubMed ID: 16943682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease.
    Elumalai R; Periasamy S; Ramanathan G; Lakkakula BV
    J Renal Inj Prev; 2014; 3(3):69-73. PubMed ID: 25340172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease.
    Reiterová J; Obeidová H; Lenícek M; Stekrová J; Merta M; Maixnerová D; Vítek L; Viklický O; Tesar V
    Kidney Blood Press Res; 2008; 31(6):398-403. PubMed ID: 19060482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of the endothelin-converting enzyme-1 gene polymorphism on the progression of autosomal dominant polycystic kidney disease.
    Reiterová J; Merta M; Stekrová J; Tesar V; Kmentová D; Ríhová Z; Rysavá R; Viklický O
    Ren Fail; 2006; 28(1):21-4. PubMed ID: 16526315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Angiotensin II Type 1 Receptor A1166C Polymorphism in Autosomal Dominant Polycystic Kidney Disease.
    Sasidharan A; Mv B; Mani R; P S
    Cureus; 2023 Jun; 15(6):e41136. PubMed ID: 37519589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.
    Blanchette CM; Liang C; Lubeck DP; Newsome B; Rossetti S; Gu X; Gutierrez B; Lin ND
    Drugs Context; 2015; 4():212275. PubMed ID: 25922609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifier effect of the Glu298Asp polymorphism of endothelial nitric oxide synthase gene in autosomal-dominant polycystic kidney disease.
    Stefanakis N; Ziroyiannis P; Trygonis S; Lamnissou K
    Nephron Clin Pract; 2008; 110(2):c101-6. PubMed ID: 18815450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Infection in Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease Patients: Progression of Kidney Disease.
    Lai S; Tinti F; Perrotta AM; Salomone L; Cianci R; Izzo P; Izzo S; Izzo L; De Intinis C; Pellicano C; Gigante A
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
    Knight T; Schaefer C; Krasa H; Oberdhan D; Chapman A; Perrone RD
    Clinicoecon Outcomes Res; 2015; 7():123-32. PubMed ID: 25759590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin in polycystic kidney disease.
    Chang MY; Ong ACM
    Contrib Nephrol; 2011; 172():200-209. PubMed ID: 21894000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease.
    Ali H; Hussain N; Naim M; Zayed M; Al-Mulla F; Kehinde EO; Seaburg LM; Sundsbak JL; Harris PC
    BMC Nephrol; 2015 Mar; 16():26. PubMed ID: 25880449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.